Clinical Trials Now Enrolling


BGB-58067 in Newly Diagnosed Glioblastoma

Learn More

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT07485049 to view inclusion criteria and additional study details.


SILEVERTINIB (BDTX-1535) FOR HIGH-GRADE GLIOMA AND GLIOBLASTOMA

Learn More

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT06072586 to view inclusion criteria and additional study details.


Risvutatug Rezetecan in Recurrent Grade 4 Glioma and in Brain Metastases

Learn More

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT07268053 to view inclusion criteria and additional study details.


QUISINOSTAT FOR GLIOBLASTOMA

Learn More

Status: Not Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT06824662 to view inclusion criteria and additional study details.


Emavusertib (CA-4948) in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma

Learn More

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT06883747 to view inclusion criteria and additional study details.


Gliofocus – Phase 3 Study of Niraparib for Glioblastoma

Learn More

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT06388733 to view inclusion criteria and additional study details.


BMS-986504 in Recurrent Glioblastoma

Learn More

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT06883747 to view inclusion criteria and additional study details.


Abemaciclib in Newly Diagnosed Meningioma Patients

Learn more

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT05940493 to view inclusion criteria and additional study details.


SONODYNAMIC THERAPY IN RECURRENT HIGH-GRADE GLIOMA

Learn More

Status: Not Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT04559685 to view inclusion criteria and additional study details.


RADIATION THERAPY VS. OBSERVATION FOR NEWLY DIAGNOSED MENINGIOMA

Learn More

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT03180268 to view inclusion criteria and additional study details.


RADIATION THERAPY PLANNING WITH FLUCICLOVINE PET FOR NEWLY DIAGNOSED GLIOBLASTOMA

Learn More

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT04840069 to view inclusion criteria and additional study details.


RADIATION THERAPY FOR BRAIN METASTASES

Learn More

Status: Active, Not Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT05438212 to view inclusion criteria and additional study details.


SMO/AKT/ NF2/CDK INHIBITORS FOR PROGRESSIVE MENINGIOMAS

Learn More

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT02523014 to view inclusion criteria and additional study details.


SAFUSIDENIB (AB-218) FOR IDH1 MUTANT GLIOMA

Learn More

Status: Recruiting

Visit ClinicalTrials.gov or use NCT identifier NCT05303519 to view inclusion criteria and additional study details.